ABSTRACT − Urinary steroid levels were investigated in the treatment of CKD-501, a new anti-diabetic drug candidate.
Type-2 diabetes evolves from a state of insulin resistance with hyperinsulinemia necessary to maintain glucose tolerance. Type-2 diabetes is manifested when insulin secretion fails to meet the demands, with consequent hyperglycemia and eventual pancreatic β-cell failure (Tomilson et al., 2008) . Recent findings on the progression of type-2 diabetes mellitus indicate that the insulin resistance in peripheral tissues induces compensatory hyperinsulinemia, followed by β-islet cell failure, initially leading to prandial pain and subsequently to obvious fasting hyperglycemia (Harris et al., 1998; Jay et al., 2007) . Peroxisome proliferator-activated receptors (PPARs), which are largely expressed in adipose tissue in comparison to the skeletal muscle and liver tissue, are ligand-inducible transcription factors that belong to the nuclear hormone receptor superfamily (Hevener et al., 2007; Norgren et al., 2004) . Thiazolidinediones (TZDs)-based PPAR activators, such as CKD-501, rosiglitazone, and pioglitazone, are believed to intensify the action of insulin, thus promoting the utilization of glucose in peripheral tissues, and as a result, are therapeutically useful in the management of type-2 diabetes (Ferre et al., 2004; Orasanu et al., 2008) . In the human ACTH-responsive NCI h295 adrenocortical cancer cell line, TZDs decrease proliferation and viability but increase ACTH receptor (MC2R) expression, cortisol secretion, and apoptosis (Betz et al., 2005) .
CKD-501 is a new anti-diabetic drug candidate. Its key ingredient is lobeglitazone sulfate, and its mechanism is PPAR gamma agonist. The structure of CKD-501 is given in Figure  1 . CKD-501 might improve the hyperglycemia by increasing GLUT-5 (Glucose Transporter 5) translocation, leading to the stimulation of glucose transport, and the elevation of intracellular calcium level might play an important role in this stimulation. CKD-501, glytazone family insulin sensitizor, enhances insulin sensitivity, glucose homeostasis, and it shows fewer side effects (hypoglycemia, shock etc) when compared with that of other anti-diabetic drugs. Furthermore, it also has potent triglyceride lowering activity and significantly improves the half-life when compared to rosiglitazone.
It has been reported that the steroid levels increase in the treatment of anti-diabetic drugs. Steroids are involved in the glucose and lipid metabolism and they are also a part of metabolites of lipids. Excess intake of glucose and fat plays a crucial role in the genesis of diabetes; inversely their level and related steroid level could be changed in the biological fluids after anti-diabetic drug treatment. Besides their well-known effects on insulin sensitivity and energy metabolism, TZDs have also been reported to modulate steroid production in gonad tissues. For example, TZDs stimulate progesterone secretion in MA-10 Leydig tumor cells (Freeman et al., 2003; Kempna et al., 2007) J. Pharm. Invest., Vol. 41, No. 1 (2011) and ovarian cells (Froment et al., 2003) . In this study, the urinary steroid levels were monitored to check the effect of CKD-501 using gas chromatography-mass spectrometry. CKD-501 is a new drug candidate in the category of anti-diabetic drugs. Hence, this monitoring process can provide useful information regarding the suitability of drug action.
Materials and Methods

Subjects
Male subjects (n=18), were recruited for this study. CKD-501 was orally administered at the dosage of 1, 2 and 4 mg/day for 7 days. The urine was collected before and at the end of drug treatment, 6 hr on 7 th day. The urine was collected again after stopping the drug administration (8 day, 0 hr). The collected urine was stored at -20 o C till the time of analysis.
Reagents
Steroids were purchased from Steraloids Inc. (Newport, R.I., USA). β-glucuronidase (β-glucuronidase activity: 400-600 U/ mL) was purchased from Roche Diagnostics GmbH (Penzberg, Germany). N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA), ammonium iodide (NH 4 I) and dithioerythreitol (DTE) were also supplied by Sigma-Aldrich Chemicals Co. (St. Louis, MO, USA). Methanol, ethyl acetate and n-hexane were bought from SK Chemicals (Ulsan, Republic of Korea, HPLC grade). Ultrapure water (18.2 MΩ) was obtained using MilliQ apparatus from Millipore (Milford, USA).
Quantitative analysis of urinary steroids Androgen, estrogen, progestins and corticosteroids were quantified in urine by following the method reported (Moon et al., 2009 ). Prior to sample preparation, 20 µL of seven internal standard mixtures (d 3 -testosterone and d 4 -estradiol 1 µg/mL, methyltestosterone, d 6 -cholesterol and d 9 -progesterone 10 µg/ mL, d 4 -cortisol and d 8 -17α-OH-progesterone 5 µg/mL) was added to 0.5 mL of urine. Solid phase extraction (SPE) was carried out using an Oasis HLB cartridge (Waters, Milford, USA). The cartridge was preconditioned with 2 mL of methanol (HPLC grade) and 2 mL of deionized water. After preconditioning, the sample was loaded in to the cartridge, and the solutes were eluted twice with 2 mL of methanol. This was followed by evaporation under a gentle stream of nitrogen gas. After adding 1 mL of Phosphate buffer (0.2 M, pH 7.2) and 50 µL of β-glucuronidase to the residue, enzyme hydrolysis was carried out at 55 o C for 1 h. Liquid-liquid extraction, using 2.5 mL of ethylacetate:n-hexane (2:3), was then performed twice. The organic phase was separated by centrifuging for 5 min at 2500 rpm; and after freezing (-25 o C) for 5 min, the supernatant was transferred. The supernatant was dried using a gentle stream of nitrogen gas at 37 o C, before being maintained in a vacuum dessicator over P 2 O 5 /KOH for at least 30 min. For derivatization, a 40 µL mixture of MSTFA, NH 4 I and DTE (500:4:2, v/w/w) was added to the dried residue and reacted at 60 0 C for 20 min. Next, a 2 µL of aliquot was used for the gas chromatography-mass spectrometry (GC-MS). The urinary steroids were analyzed by GC-MS using an Agilent 6890 series gas chromatograph and an Agilent 5975 series mass selective detector. The samples were injected into a fused-silica capillary column that was coated with cross linked methyl silicone 
Urinary creatinine value
All the concentrations calculated from the calibration curves were revised according to the respective urinary creatinine values. The urinary creatinine value of each sample was measured by Jaffe method (Kassirer et al., 1971) .
Results
The urinary steroids have shown an increase in their levels upon drug administration, and have shown a decline after stopping the drug administration. The total ion chromatogram obtained was shown in Figure 2 . Among the four major groups of steroids analyzed, a prominent change was observed in the urinary corticoids concentration profile. A significant increase in urinary corticoid levels was found in all the three dosage groups on the last day of drug administration in comparison to their levels before drug administration and immediately after drug withdrawal. The significant pattern of changes in corticoid levels in low dosage group (1 mg/day) were detailed in Figure 3 . In the medium dosage group (2 mg/day), similar pat- Figure 2 . A representative total ion chromatogram of steroids detected by GC-MS in 7th day 6th hour urine of the drug treated subjects. [BT: before drug treatment, AT: after drug treatment, 7d 6hr: last day of drug treatment; *P≤0.05, **P≤0.01, ***P≤0.001] J. Pharm. Invest., Vol. 41, No. 1 (2011) tern of changes in corticosteroid levels with more significance was observed (Fig. 4) . The high dosage group (4 mg/day) also has shown the similar pattern as compared to results obtained in other two dosage groups (Fig. 5) . Among the other groups of steroids besides corticosteroids, an androgen, dehydroepiandrosterone, has shown similar pattern of results as those of corticosteroids in all the three dosage groups (Fig. 6) . The representative extracted ion chromatograms of the nine corticoids and an androgen, DHEA were shown in Figure 7 .
Method validation
Calibration curves were generated for all analytes at different concentrations in the range of 0.1~3000 ng/mL. They were found to be linear (correlation coefficient, r 2 >0.989). Most compounds had an LOQ in the 0.05 ~2.0 ng/mL ranges, while those of DHEA, Epi-An, 5α-dione, αββ-diol ranged between 5.0 and 50 ng/mL. Assay precisions and accuracies were determined by analyzing three QC samples at different concentrations of the individual steroids (5, 20, 100, 200, 500, and 2000 ng/mL). Intra-day (n=4) precisions (expressed as % CV) ranged from 0.9% to 11.2%, whereas accuracies (expressed as % bias) ranged from 95.8 to 119.1%, and inter-day (n=5) precisions (% CV) and accuracies (% bias) ranged from 1.6% to 10.5% and from 91.6% to 115.5%, respectively. Discussion CKD-501 (i.e., lobeglitazone), a potent agonist for both PPARα/γ, is a new drug that has potential clinical applications in the management of type-2 diabetes (Lee et al., 2009 ). Peroxisome proliferator-activated receptors (PPAR α, γ, and δ) are members of the nuclear receptor family and play a key role in the regulation of adipocyte differentiation, insulin sensitivity, glucose and lipid metabolism, and inflammation (Berthiaume et al., 2007; Blaschke et al., 2006; Desvergne et al., 2004) . Some anti-diabetic drugs have shown an increase in the steroid levels in biological fluids (Wang et al., 1997) . In the present study, we attempted to study the effects of CKD-50l on steroid [BT: before drug treatment, AT: after drug treatment, 7d 6hr: last day of drug treatment; *P≤0.05, **P≤0.01, ***P≤0.001] metabolism, analyzing the steroid levels in the human urine samples. According to the results obtained, of all the steroids analyzed, nine glucocorticoids and one androgen levels increased upon the drug treatment than before the drug treatment and decreased after stopping the drug treatment.
Glucocorticoids are steroidal hormones that play an essential role in whole body glucose homeostasis (Baxter et al.; 1979) and are excreted in urine. Therefore, it was thought that the effect of anti-diabetic drug could be evaluated by monitoring the changes in urinary corticosteroid levels. In practice, urinary corticosteroid level was changed by the administration of CKD-501. Similar results on the change of a corticosteroid, corticosterone level in plasma have been reported in the animal studies using lean and fatty zucker rats, in the case of rosigl- Figure 5 . Glucocorticoid metabolites detected in the urine of CKD-501 treated subjects − 4 mg/day dosage group.
[BT: before drug treatment, AT: after drug treatment, 7d 6hr: last day of drug treatment; *P≤0.05, **P≤0.01, ***P≤0.001] Figure 6 . DHEA detected in the urine of CKD-501 treated subjects − 1, 2, 4 mg/day dosage groups.
[BT: before drug treatment, AT: after drug treatment, 7d 6hr: last day of drug treatment; *P≤0.05, **P≤0.01, ***P≤0.001] J. Pharm. Invest., Vol. 41, No. 1 (2011) itazone treatment (Wang et al., 1997) . In agreement with the published data we attained the results with a broader range of nine corticosteroids in human study. The coticosteroids have shown a significant pattern of increase in their urinary concentration upon administration of a novel anti-diabetic drug, CKD-501 at three dosages in human, thus depicting the effectiveness of the drug upon steroid metabolism.
Another steroid which showed a urinary level change by anti-diabetic drug administration was DHEA (dehydroepiandrosterone), a kind of androgen. DHEA exerts beneficial effects on blood glucose levels and insulin sensitivity in obese rodents and humans, resembling the effects of peroxisome proliferator-activated receptor (PPAR) ligands (Dzhamilja et al., 2006) . A growing body of evidence indicates that DHEA plays a significant role in reducing the age-related increase in insulin levels, insulin resistance, and blood glucose; which, in turn, helps to reduce the risks of syndrome X, obesity, cardio vascular diseases, and diabetes. The inhibitory effect of DHEA on complex 1 may also partly explain possible anti-diabetic effects of DHEA (Galina et al., 2005) . Therefore, it is also possible that the action of anti-diabetic drug could be also checked by the change in urinary DHEA level.
In summary, our results indicate that the levels of corticoids and an androgen, DHEA are increased upon the treatment with CKD-501. Thus, an increase in those steroids, upon CKD-501 treatment, assists in maintaining the glucose balance along with its insulin sensitizer activity and their urinary levels could be used for the monitoring of anti-diabetic drug effects. Figure 7 . The representative extracted ion chromatograms of the glucocorticoids and an androgen detected by GC-MS in 7 th day 6th hour urine of the drug treated subjects.
[Glucocorticoids: cortisol, tetrahydrocortisone, tetrahydrocortisol, α-cortolone, β-cortolone, 20-α-dihydrocortisone, α-cortol, β-cortol, 20-α-dihydrocortisol.; Androgen: dehydroepiandrosterone].
